Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9165647 | 1.00 | IDO1 (0.46) | IDO1PDPK1CA1CA2CYP11B2 | |
| SCHEMBL9167813 | 0.88 | IDO1 (0.49) | IDO1CHRNA7 | |
| SCHEMBL1756937 | 0.88 | IDO1 (0.49) | IDO1CHRNA7 | |
| SCHEMBL9159886 | 0.88 | IDO1 (0.49) | IDO1CHRNA7 | |
| SCHEMBL1697825 | 0.79 | IDO1 (0.46) | IDO1PDPK1CA1CA2CYP11B2 | |
| SCHEMBL8657446 | 0.79 | MAOA (0.50) | IDO1PDPK1CA1CA2CYP11B2 | |
| SCHEMBL21630391 | 0.79 | IDO1 (0.46) | IDO1PDPK1CA1CA2CYP11B2 | |
| SCHEMBL9160631 | 0.78 | CHRNB2 (0.44) | — | |
| SCHEMBL4656200 | 0.78 | CHRNB2 (0.44) | — | |
| Hydrochloric Acid SCHEMBL20843623 | 0.78 | IDO1 (0.47) | IDO1PDPK1CYP11B2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | claimed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | claimed |
| US-20160272632-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | claimed |
| EP-2976339-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | claimed |
| WO-2014146491-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | claimed |
| EP-1252890-B1 | REMEDIES OR PREVENTIVES FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA (JP) | 2008-07-02 | — | — | EP | claimed |
| US-20070031415-A1 | Regulation of interaction between rapl and rap1 | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1252889-B1 | REMEDIES OR PREVENTIVES FOR PULMONARY INSUFFICIENCY CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA (JP) | 2006-08-09 | — | — | EP | claimed |
| EP-1252891-B1 | Use of DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES FOR the prevention and treatment of LIVER DISEASES | ISHIHARA SANGYO KAISHA (JP) | 2005-10-05 | — | — | EP | claimed |
| EP-1557670-A1 | REGULATION OF INTERACTION BETWEEN RAPL AND Rap1 | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2005-07-27 | — | — | EP | claimed |
| EP-1252889-A1 | REMEDIES OR PREVENTIVES FOR PULMONARY INSUFFICIENCY CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2002-10-30 | — | — | EP | claimed |
| EP-1252890-A1 | REMEDIES OR PREVENTIVES FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2002-10-30 | — | — | EP | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| EP-0563731-B1 | Medicaments containing polyhydroxymethylene-derivatives, process for their manufacture and use thereof | HOECHST AG (DE) | 1995-11-15 | — | — | EP | claimed |
| US-5401498-A | Anticholesterol agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-28 | — | — | US | claimed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070031415-A1 | Regulation of interaction between rapl and rap1 | RAP1A, RAPGEF3, RAPGEF4 | IDO1 3526/4885PDPK1 1512/4885CA1 4704/4885 |
| US-20160272632-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | IDO1 405/4885PDPK1 244/4885CA1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.